Moors & Cabot, Inc. Editas Medicine, Inc. Transaction History

Moors & Cabot, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$8.32 - $13.21 $83,258 - $132,192	10,007 New	10,007 $88,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $138,086 - $211,004	-5,201 Closed	0 $0
Q3 2021 Dec 08, 2021	BUY	$39.27 - $72.94 $204,243 - $379,360	5,201 New	5,201 $214,000
Q3 2021 Nov 05, 2021	SELL	$39.27 - $72.94 $155,155 - $288,185	-3,951 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$31.29 - $56.64 $123,626 - $223,784	3,951 New	3,951 $224,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.